{
    "nct_id": "NCT03321045",
    "official_title": "PET Imaging with 89Zr-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness",
    "inclusion_criteria": "* Be at least 18 years of age.\n* Diagnosis of HER2 positive breast cancer as defined by to American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) 2018 guidelines: Immunohistochemistry (IHC) 3+ OR Single prove In situ hybridization (ISH) with average HER2 copy number >= 6 OR dual probe ISH with both average HER2 copy number >= 4 AND HER2 to CEP17 ratio >=2\n* Patients eligible for radiation therapy or systemic therapy using a regimen containing at least one anti-HER2 agent\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 and 1\n* Ejection fraction greater than 50% by echocardiogram or multiple-gated acquisition (MUGA) scans\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Inability to provide informed consent\n* Pregnancy\n* Inability to lie still for the imaging study\n* Weight over 350 lbs., due to the scanner bore size\n* Contraindication for MRI study (e.g. non-removable metal implants or certain tattoos)",
    "miscellaneous_criteria": ""
}